LivaNova’s Strategic Growth Plan and OSA Device Commercialization Justify Buy Rating

Michael Matson, an analyst from Needham, reiterated the Buy rating on LivaNova. The associated price target remains the same with $64.00.

Michael Matson has given his Buy rating due to a combination of factors that highlight LivaNova’s promising growth prospects. The company has laid out a strategic plan to achieve high-single-digit growth in its core business and obstructive sleep apnea (OSA) segment from 2025 to 2030, aligning with market expectations.
Furthermore, LivaNova’s decision to independently commercialize its OSA device is anticipated to initially impact earnings per share (EPS) growth negatively until mid-2028. However, this move is expected to become a positive driver for EPS growth as sales increase significantly by 2030. The investor day presentations underscored LivaNova’s capability to maintain robust near-term growth while setting the stage for substantial long-term acceleration, particularly in the OSA and difficult-to-treat depression (DTD) markets, justifying the Buy rating.

Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, Penumbra, and TransMedics Group. According to TipRanks, Matson has an average return of -2.5% and a 39.96% success rate on recommended stocks.

In another report released on November 6, Robert W. Baird also maintained a Buy rating on the stock with a $63.00 price target.